Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 204

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 204
---
 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least one year, including the
holding period of any prior owner other than one of our affiliates, is entitled to sell his, her or its shares under Rule 144 without
complying with the provisions relating to the availability of current public information or with any other conditions under Rule 144.
Therefore, unless subject to a lock-up agreement or otherwise restricted, such shares may be sold immediately upon the closing of this
offering.

Rule 701

In general, under Rule 701,
any of our employees, directors, officers, consultants or advisors who received or purchased Ordinary Shares from us under our incentive
option plan or other written agreement before the closing of this offering is entitled to resell these shares.

The SEC has indicated that
Rule 701 will apply to typical share options granted by an issuer before it becomes subject to the reporting requirements of the
Exchange Act, along with the shares acquired upon exercise of these options, including exercises after the closing of this offering.
Securities issued in reliance on Rule 701 are restricted securities and, subject to the contractual restrictions described above
(see “Lock-Up Agreements”), may be sold beginning 90 days after the closing of this offering in reliance on Rule 144
by:

| ● | persons other than affiliates, 
 without restriction; and       |

| ● | affiliates, subject to                                                                                                        
 the manner-of-sale, current public information and filing requirements of Rule 144, in each case, without compliance with the 
 six-month holding period requirement of Rule 144.                                                                             |

<div align='center'>125</div>

Investors’ Rights Agreement

On February 5, 2016, we entered
into an Investors’ Rights Agreement, or the IRA, with several of our shareholders, pursuant to which the holders
of a total of 946,392 of our Ordinary Shares will have a right to require that we register these shares under the Securities Act under
specific circumstances and will have incidental registration rights as described below. After a registration pursuant
to these rights, these shares will become freely tradable without restriction.

Demand Registration Rights

At any time following nine
(9) months after the closing of this offering, subject to any lock-up agreements, at the request of the holders of a majority of: (i)
any Ordinary shares of the Company issued upon conversion of any Series A Preferred Shares, Series B Preferred Shares, Series C Preferred
Shares, Series D-1 Preferred